UNSPSC 41171602: Coagulase plasma

In this classification, a Coagulase plasma connotes a device used to create staphylothrombin, which enables the enzyme protease to convert fibrinogen, a plasma protein produced by the liver, to fibrin. This results in clotting of the blood. US FDA regulates Coagulase plasma under 21 CFR 866.2160 and under FDA product code JTL.

UNSPSC 41171602 Coagulase plasma, a Commodity code, covers blood-derived testing reagents used in clinical and laboratory coagulation assays, which state and local health departments, public health laboratories, hospital systems, and clinical diagnostic facilities procure for routine hemostasis testing and anticoagulation monitoring. The code encompasses plasma products specifically formulated for quality control and calibration in PT, aPTT, and thrombin time testing protocols. State and local buyers under this code include public health agencies managing centralized laboratory networks, county and municipal hospital procurement offices, state laboratory certification programs, and regional diagnostic reference centers that rely on standardized coagulation plasma to maintain test accuracy across distributed clinical sites.

The source provides no recent state and local contract opportunities tagged to this code. Activity under UNSPSC 41171602 appears limited or episodic in public procurement records, suggesting that coagulase plasma procurement either occurs through standing laboratory supply agreements, cooperative purchasing vehicles managed at the state level, or is consolidated within broader clinical laboratory reagent contracts that carry different UNSPSC classifications. Firms pursuing this market should monitor state health department and public hospital system RFPs and cooperative purchasing catalogs for laboratory reagent bundles, as individual plasma product solicitations may not appear as discrete opportunities in public notice boards.